» Articles » PMID: 36990486

Comparing Pharmaceutical Company Payments in the Four UK Countries: a Cross-sectional and Social Network Analysis

Overview
Journal BMJ Open
Specialty General Medicine
Date 2023 Mar 29
PMID 36990486
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To examine the characteristics of pharmaceutical payments to healthcare and patient organisations in the four UK countries. Compare companies spending the most; types of organisations receiving payments and types of payments in the four countries. Measure the extent to which companies target payments at the same recipients in each country and whether it differs depending on the type of recipient.

Design: Cross-sectional comparative and social network analysis.

Setting: England, Scotland, Wales, Northern Ireland.

Participants: 100 donors (pharmaceutical companies) reporting payments to 4229 recipients (healthcare organisations and patient organisations) in 2015.

Main Outcome Measures: For each country: payment totals and distribution; average number of common recipients between companies; share of payments to organisations fulfilling different roles in the health ecosystem and payments for different activities.

Results: Companies prioritised different types of recipient and different types of activity in each country. There were significant differences in the distribution of payments across the four countries, even for similar types of recipients. Recipients in England and Wales received smaller individual payments than in Scotland and Northern Ireland. Overall, targeting shared recipients occurred most frequently in England, but was also common in certain pockets of each country's health ecosystem. We found evidence of reporting errors in Disclosure UK.

Conclusions: Our findings suggest a strategic approach to payments tailored to countries' policy and decision-making context, indicating there may be specific vulnerabilities to financial conflicts of interest at subnational level. Payment differences between countries may be occurring in other countries, particularly those with decentralised health systems and/or high levels of independence across its decision-making authorities. We call for a single database containing all recipient types, full location details and published with associated descriptive and network statistics.

Citing Articles

Unpicking influence and conflicts of interest in prescribing.

Lawson E Br J Gen Pract. 2024; 74(748):483.

PMID: 39481902 PMC: 11526742. DOI: 10.3399/bjgp24X739677.


Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database.

Ozieranski P, Saghy E, Mulinari S PLoS One. 2023; 18(11):e0290022.

PMID: 37910526 PMC: 10619808. DOI: 10.1371/journal.pone.0290022.


Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.

Gentilini A, Parvanova I BMJ Open. 2023; 13(6):e071138.

PMID: 37369404 PMC: 10410975. DOI: 10.1136/bmjopen-2022-071138.


Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.

Rickard E, Carmel E, Ozieranski P BMJ Open. 2023; 13(3):e061591.

PMID: 36990486 PMC: 10069501. DOI: 10.1136/bmjopen-2022-061591.

References
1.
Moberly T . CCGs fail to declare pharma funding. BMJ. 2018; 360:j5911. DOI: 10.1136/bmj.j5911. View

2.
Cheng T, Boelitz K, Rybin D, Menard M, Kalish J, Siracuse J . Nationwide patterns in industry payments to academic vascular surgeons. J Vasc Surg. 2020; 73(2):675-681. DOI: 10.1016/j.jvs.2020.04.527. View

3.
Mulinari S, Vilhelmsson A, Rickard E, Ozieranski P . Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. PLoS One. 2020; 15(6):e0235021. PMC: 7313941. DOI: 10.1371/journal.pone.0235021. View

4.
Lexchin J . Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis. J Pharm Policy Pract. 2018; 11:5. PMC: 5848527. DOI: 10.1186/s40545-018-0132-3. View

5.
Fabbri A, Grundy Q, Mintzes B, Swandari S, Moynihan R, Walkom E . A cross-sectional analysis of pharmaceutical industry-funded events for health professionals in Australia. BMJ Open. 2017; 7(6):e016701. PMC: 5726125. DOI: 10.1136/bmjopen-2017-016701. View